|
gptkbp:instanceOf
|
gptkb:drug
statin
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:C10AA07
|
|
gptkbp:brand
|
gptkb:Crestor
|
|
gptkbp:CASNumber
|
287714-41-4
|
|
gptkbp:chemicalFormula
|
contains sulfonamide group
contains fluorophenyl group
|
|
gptkbp:contraindication
|
gptkb:liver_disease
pregnancy
breastfeeding
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
gptkb:Shionogi
|
|
gptkbp:drugClass
|
lipid-lowering agent
|
|
gptkbp:eliminationHalfLife
|
19 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1999
|
|
gptkbp:hasMolecularFormula
|
C22H28FN3O6S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rosuvastatin
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:warfarin
gptkb:gemfibrozil
antacids
|
|
gptkbp:KEGGID
|
gptkb:D01968
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:AstraZeneca
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
88%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1200968
gptkb:DB01098
446157
|
|
gptkbp:riskFactor
|
gptkb:diabetes_mellitus
liver dysfunction
rhabdomyolysis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
muscle pain
liver enzyme abnormalities
myalgia
|
|
gptkbp:synonym
|
gptkb:ZD4522
gptkb:rosuvastatin_calcium
|
|
gptkbp:UNII
|
A6XN5QXW3E
|
|
gptkbp:usedFor
|
gptkb:familial_hypercholesterolemia
prevention of cardiovascular disease
|
|
gptkbp:bfsParent
|
gptkb:CHEBI:46787
|
|
gptkbp:bfsLayer
|
5
|